Compugen announces discovery of biomarkers for early pre-clinical detection of drug-induced kidney toxicity
The Company plans to initiate commercialization during the first half of 2009.
Tel Aviv, Israel – June 26, 2008 – Compugen Ltd. (NASDAQ: CGEN) announced today the discovery and experimental confirmation of a novel combination of four biomarkers for early detection of drug-induced nephrotoxicity. Data demonstrate that the biomarker signature may enable a much earlier prediction of drug-induced kidney toxicity during pre-clinical trials in rats in comparison to traditional diagnostic methods such as histopathology or clinical chemistry.
“Improved pre-clinical biomarkers for kidney toxicity would dramatically reduce the time and costs required to prioritize and select lead candidates for progression through drug development stages,” said Anat Cohen-Dayag, Ph.D., Vice President of Diagnostic Biomarkers and Drug Targets at Compugen Ltd.
The biomarkers were discovered through the use of Compugen’s Nucleic Acid Testing (NAT) Discovery Platform. A key component of the discovery effort was the integration of proprietary expression and clinical data derived from biological samples provided by Teva Pharmaceutical Industries Ltd. These samples were generated by Teva in a preclinical study designed specifically for this project pursuant to a Collaborative Research Agreement between Compugen and Teva. Using various expression profile datasets, as well as statistical and machine-learning tools, a classifier consisting of a novel combination of four biomarkers was identified with a sensitivity of 80% and a specificity of more than 85%.
Source: Compugen Ltd.